The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2026 | Highlights from ELCC 2026: iza-bren plus serplulimab
Ippokratis Korantzis, MD, PhD, European Interbalkan Medical Center, Thessaloniki, Greece, discusses key takeaways from the 2026 ELCC meeting, highlighting data showing significant responses for an antibody-drug conjugate izalontamab brengitecan (iza-bren) and anti-PD-1 antibody serplulimab combination in extensive-stage small-cell lung cancer (ES-SCLC) (NCT06437509). This interview took place at the 2026 European Lung Cancer Congress in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
